Association of the polymorphism of the Toll‐like receptor (TLR)‐3 and TLR‐9 genes with hepatitis C virus‐specific cell‐mediated immunity outcomes among Egyptian health‐care workers
We previously reported that TLR3.rs3775290 ‘CC’ genotype was associated with HCV chronicity, while TLR9 gene played no role in this infection. Herein, we show a significant association between the outcome of the HCV‐specific cell‐mediated immune (CMI) response and TLR9.rs5743836 genotype among the t...
Saved in:
| Published in | Clinical and experimental immunology Vol. 203; no. 1; pp. 3 - 12 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Oxford University Press
01.01.2021
John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | We previously reported that TLR3.rs3775290 ‘CC’ genotype was associated with HCV chronicity, while TLR9 gene played no role in this infection. Herein, we show a significant association between the outcome of the HCV‐specific cell‐mediated immune (CMI) response and TLR9.rs5743836 genotype among the total responding subjects with different HCV states (p=0.005) and among the chronic HCV patients (p=0.044). We conclude that TLR9.rs5743836 SNP; but not TLR3.rs3775290 or TLR9.rs352140 genotypes; could predict the outcome of HCV‐specific CMI responses among HCV genotype‐4‐infected Egyptians.
Summary
Variations in the immune response could explain resistance to hepatitis C virus (HCV) infection. Toll‐like receptor gene (TLR)‐3 is an innate detector of dsRNA viruses, and the TLR‐9 gene recognizes bacterial and viral unmethylated cytosine–phosphate–guanosine (CpG) motifs. We previously reported that the TLR‐3.rs3775290 CC genotype was associated with HCV chronicity and that the TLR‐9 gene played no major role in this infection. This study identified the role of TLR‐3.rs3775290 (c.1377C/T), TLR‐9.rs5743836 (−1237T→C) and TLR‐9.rs352140 (G2848A) gene polymorphisms in predicting the outcome of HCV‐specific cell‐mediated immunity (CMI) among Egyptian health‐care workers (HCWs). We enrolled 265 HCWs in this study and divided them into four groups. Group 1: 140 seronegative‐aviraemic HCWs; group 2: 20 seronegative‐viraemic HCWs; group 3: 35 subjects with spontaneously resolved HCV infection; and group 4: 70 chronic HCV HCWs (patients). All subjects were genotyped by polymerase chain reaction–restriction fragment length polymorphism (PCR‐RFLP) analysis for the TLR‐3.rs3775290, TLR‐9.rs5743836 and TLR‐9.rs352140 single nucleotide polymorphisms (SNPs). We also quantified HCV‐specific CMI in the four groups using an interferon (IFN)‐γ enzyme‐linked immunospot (ELISPOT) assay in response to nine HCV genotype 4a, overlapping 15mer peptide pools covering the whole viral genome. No statistically significant difference was found between CMI‐responding subjects with different HCV states and TLR‐3.rs3775290 or TLR‐9.rs352140 genotypes. However, there was a significant relationship between the outcome of the HCV‐specific CMI and the TLR‐9.rs5743836 genotype among the responding subjects (P = 0·005) and the chronic HCV patients (P = 0·044). In conclusion, TLR‐9.rs5743836 SNP, but not TLR‐3.rs3775290 or TLR‐9.rs352140 genotypes, could predict the outcome of HCV‐specific CMI responses among Egyptians infected with genotype‐4. |
|---|---|
| AbstractList | Variations in the immune response could explain resistance to hepatitis C virus (HCV) infection. Toll-like receptor gene (TLR)-3 is an innate detector of dsRNA viruses, and the TLR-9 gene recognizes bacterial and viral unmethylated cytosine-phosphate-guanosine (CpG) motifs. We previously reported that the TLR-3.rs3775290 CC genotype was associated with HCV chronicity and that the TLR-9 gene played no major role in this infection. This study identified the role of TLR-3.rs3775290 (c.1377C/T), TLR-9.rs5743836 (-1237T→C) and TLR-9.rs352140 (G2848A) gene polymorphisms in predicting the outcome of HCV-specific cell-mediated immunity (CMI) among Egyptian health-care workers (HCWs). We enrolled 265 HCWs in this study and divided them into four groups. Group 1: 140 seronegative-aviraemic HCWs; group 2: 20 seronegative-viraemic HCWs; group 3: 35 subjects with spontaneously resolved HCV infection; and group 4: 70 chronic HCV HCWs (patients). All subjects were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis for the TLR-3.rs3775290, TLR-9.rs5743836 and TLR-9.rs352140 single nucleotide polymorphisms (SNPs). We also quantified HCV-specific CMI in the four groups using an interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assay in response to nine HCV genotype 4a, overlapping 15mer peptide pools covering the whole viral genome. No statistically significant difference was found between CMI-responding subjects with different HCV states and TLR-3.rs3775290 or TLR-9.rs352140 genotypes. However, there was a significant relationship between the outcome of the HCV-specific CMI and the TLR-9.rs5743836 genotype among the responding subjects (P = 0·005) and the chronic HCV patients (P = 0·044). In conclusion, TLR-9.rs5743836 SNP, but not TLR-3.rs3775290 or TLR-9.rs352140 genotypes, could predict the outcome of HCV-specific CMI responses among Egyptians infected with genotype-4.Variations in the immune response could explain resistance to hepatitis C virus (HCV) infection. Toll-like receptor gene (TLR)-3 is an innate detector of dsRNA viruses, and the TLR-9 gene recognizes bacterial and viral unmethylated cytosine-phosphate-guanosine (CpG) motifs. We previously reported that the TLR-3.rs3775290 CC genotype was associated with HCV chronicity and that the TLR-9 gene played no major role in this infection. This study identified the role of TLR-3.rs3775290 (c.1377C/T), TLR-9.rs5743836 (-1237T→C) and TLR-9.rs352140 (G2848A) gene polymorphisms in predicting the outcome of HCV-specific cell-mediated immunity (CMI) among Egyptian health-care workers (HCWs). We enrolled 265 HCWs in this study and divided them into four groups. Group 1: 140 seronegative-aviraemic HCWs; group 2: 20 seronegative-viraemic HCWs; group 3: 35 subjects with spontaneously resolved HCV infection; and group 4: 70 chronic HCV HCWs (patients). All subjects were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis for the TLR-3.rs3775290, TLR-9.rs5743836 and TLR-9.rs352140 single nucleotide polymorphisms (SNPs). We also quantified HCV-specific CMI in the four groups using an interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assay in response to nine HCV genotype 4a, overlapping 15mer peptide pools covering the whole viral genome. No statistically significant difference was found between CMI-responding subjects with different HCV states and TLR-3.rs3775290 or TLR-9.rs352140 genotypes. However, there was a significant relationship between the outcome of the HCV-specific CMI and the TLR-9.rs5743836 genotype among the responding subjects (P = 0·005) and the chronic HCV patients (P = 0·044). In conclusion, TLR-9.rs5743836 SNP, but not TLR-3.rs3775290 or TLR-9.rs352140 genotypes, could predict the outcome of HCV-specific CMI responses among Egyptians infected with genotype-4. Variations in the immune response could explain resistance to hepatitis C virus (HCV) infection. Toll-like receptor gene (TLR)-3 is an innate detector of dsRNA viruses, and the TLR-9 gene recognizes bacterial and viral unmethylated cytosine-phosphate-guanosine (CpG) motifs. We previously reported that the TLR-3.rs3775290 CC genotype was associated with HCV chronicity and that the TLR-9 gene played no major role in this infection. This study identified the role of TLR-3.rs3775290 (c.1377C/T), TLR-9.rs5743836 (-1237T→C) and TLR-9.rs352140 (G2848A) gene polymorphisms in predicting the outcome of HCV-specific cell-mediated immunity (CMI) among Egyptian health-care workers (HCWs). We enrolled 265 HCWs in this study and divided them into four groups. Group 1: 140 seronegative-aviraemic HCWs; group 2: 20 seronegative-viraemic HCWs; group 3: 35 subjects with spontaneously resolved HCV infection; and group 4: 70 chronic HCV HCWs (patients). All subjects were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis for the TLR-3.rs3775290, TLR-9.rs5743836 and TLR-9.rs352140 single nucleotide polymorphisms (SNPs). We also quantified HCV-specific CMI in the four groups using an interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assay in response to nine HCV genotype 4a, overlapping 15mer peptide pools covering the whole viral genome. No statistically significant difference was found between CMI-responding subjects with different HCV states and TLR-3.rs3775290 or TLR-9.rs352140 genotypes. However, there was a significant relationship between the outcome of the HCV-specific CMI and the TLR-9.rs5743836 genotype among the responding subjects (P = 0·005) and the chronic HCV patients (P = 0·044). In conclusion, TLR-9.rs5743836 SNP, but not TLR-3.rs3775290 or TLR-9.rs352140 genotypes, could predict the outcome of HCV-specific CMI responses among Egyptians infected with genotype-4. Variations in the immune response could explain resistance to hepatitis C virus (HCV) infection. Toll-like receptor gene (TLR)-3 is an innate detector of dsRNA viruses, and the TLR-9 gene recognizes bacterial and viral unmethylated cytosine–phosphate–guanosine (CpG) motifs. We previously reported that the TLR-3.rs3775290 CC genotype was associated with HCV chronicity and that the TLR-9 gene played no major role in this infection. This study identified the role of TLR-3.rs3775290 (c.1377C/T), TLR-9.rs5743836 (−1237T→C) and TLR-9.rs352140 (G2848A) gene polymorphisms in predicting the outcome of HCV-specific cell-mediated immunity (CMI) among Egyptian health-care workers (HCWs). We enrolled 265 HCWs in this study and divided them into four groups. Group 1: 140 seronegative-aviraemic HCWs; group 2: 20 seronegative-viraemic HCWs; group 3: 35 subjects with spontaneously resolved HCV infection; and group 4: 70 chronic HCV HCWs (patients). All subjects were genotyped by polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) analysis for the TLR-3.rs3775290, TLR-9.rs5743836 and TLR-9.rs352140 single nucleotide polymorphisms (SNPs). We also quantified HCV-specific CMI in the four groups using an interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assay in response to nine HCV genotype 4a, overlapping 15mer peptide pools covering the whole viral genome. No statistically significant difference was found between CMI-responding subjects with different HCV states and TLR-3.rs3775290 or TLR-9.rs352140 genotypes. However, there was a significant relationship between the outcome of the HCV-specific CMI and the TLR-9.rs5743836 genotype among the responding subjects (P = 0·005) and the chronic HCV patients (P = 0·044). In conclusion, TLR-9.rs5743836 SNP, but not TLR-3.rs3775290 or TLR-9.rs352140 genotypes, could predict the outcome of HCV-specific CMI responses among Egyptians infected with genotype-4. Variations in the immune response could explain resistance to hepatitis C virus (HCV) infection. Toll‐like receptor gene (TLR)‐3 is an innate detector of dsRNA viruses, and the TLR‐9 gene recognizes bacterial and viral unmethylated cytosine–phosphate–guanosine (CpG) motifs. We previously reported that the TLR‐3.rs3775290 CC genotype was associated with HCV chronicity and that the TLR‐9 gene played no major role in this infection. This study identified the role of TLR‐3.rs3775290 (c.1377C/T), TLR‐9.rs5743836 (−1237T→C) and TLR‐9.rs352140 (G2848A) gene polymorphisms in predicting the outcome of HCV‐specific cell‐mediated immunity (CMI) among Egyptian health‐care workers (HCWs). We enrolled 265 HCWs in this study and divided them into four groups. Group 1: 140 seronegative‐aviraemic HCWs; group 2: 20 seronegative‐viraemic HCWs; group 3: 35 subjects with spontaneously resolved HCV infection; and group 4: 70 chronic HCV HCWs (patients). All subjects were genotyped by polymerase chain reaction–restriction fragment length polymorphism (PCR‐RFLP) analysis for the TLR‐3.rs3775290, TLR‐9.rs5743836 and TLR‐9.rs352140 single nucleotide polymorphisms (SNPs). We also quantified HCV‐specific CMI in the four groups using an interferon (IFN)‐γ enzyme‐linked immunospot (ELISPOT) assay in response to nine HCV genotype 4a, overlapping 15mer peptide pools covering the whole viral genome. No statistically significant difference was found between CMI‐responding subjects with different HCV states and TLR‐3.rs3775290 or TLR‐9.rs352140 genotypes. However, there was a significant relationship between the outcome of the HCV‐specific CMI and the TLR‐9.rs5743836 genotype among the responding subjects (P = 0·005) and the chronic HCV patients (P = 0·044). In conclusion, TLR‐9.rs5743836 SNP, but not TLR‐3.rs3775290 or TLR‐9.rs352140 genotypes, could predict the outcome of HCV‐specific CMI responses among Egyptians infected with genotype‐4. We previously reported that TLR3.rs3775290 ‘CC’ genotype was associated with HCV chronicity, while TLR9 gene played no role in this infection. Herein, we show a significant association between the outcome of the HCV‐specific cell‐mediated immune (CMI) response and TLR9.rs5743836 genotype among the total responding subjects with different HCV states (p=0.005) and among the chronic HCV patients (p=0.044). We conclude that TLR9.rs5743836 SNP; but not TLR3.rs3775290 or TLR9.rs352140 genotypes; could predict the outcome of HCV‐specific CMI responses among HCV genotype‐4‐infected Egyptians. Summary Variations in the immune response could explain resistance to hepatitis C virus (HCV) infection. Toll‐like receptor gene (TLR)‐3 is an innate detector of dsRNA viruses, and the TLR‐9 gene recognizes bacterial and viral unmethylated cytosine–phosphate–guanosine (CpG) motifs. We previously reported that the TLR‐3.rs3775290 CC genotype was associated with HCV chronicity and that the TLR‐9 gene played no major role in this infection. This study identified the role of TLR‐3.rs3775290 (c.1377C/T), TLR‐9.rs5743836 (−1237T→C) and TLR‐9.rs352140 (G2848A) gene polymorphisms in predicting the outcome of HCV‐specific cell‐mediated immunity (CMI) among Egyptian health‐care workers (HCWs). We enrolled 265 HCWs in this study and divided them into four groups. Group 1: 140 seronegative‐aviraemic HCWs; group 2: 20 seronegative‐viraemic HCWs; group 3: 35 subjects with spontaneously resolved HCV infection; and group 4: 70 chronic HCV HCWs (patients). All subjects were genotyped by polymerase chain reaction–restriction fragment length polymorphism (PCR‐RFLP) analysis for the TLR‐3.rs3775290, TLR‐9.rs5743836 and TLR‐9.rs352140 single nucleotide polymorphisms (SNPs). We also quantified HCV‐specific CMI in the four groups using an interferon (IFN)‐γ enzyme‐linked immunospot (ELISPOT) assay in response to nine HCV genotype 4a, overlapping 15mer peptide pools covering the whole viral genome. No statistically significant difference was found between CMI‐responding subjects with different HCV states and TLR‐3.rs3775290 or TLR‐9.rs352140 genotypes. However, there was a significant relationship between the outcome of the HCV‐specific CMI and the TLR‐9.rs5743836 genotype among the responding subjects (P = 0·005) and the chronic HCV patients (P = 0·044). In conclusion, TLR‐9.rs5743836 SNP, but not TLR‐3.rs3775290 or TLR‐9.rs352140 genotypes, could predict the outcome of HCV‐specific CMI responses among Egyptians infected with genotype‐4. We previously reported that TLR3.rs3775290 ‘CC’ genotype was associated with HCV chronicity, while TLR9 gene played no role in this infection. Herein, we show a significant association between the outcome of the HCV‐specific cell‐mediated immune (CMI) response and TLR9.rs5743836 genotype among the total responding subjects with different HCV states (p=0.005) and among the chronic HCV patients (p=0.044). We conclude that TLR9.rs5743836 SNP; but not TLR3.rs3775290 or TLR9.rs352140 genotypes; could predict the outcome of HCV‐specific CMI responses among HCV genotype‐4‐infected Egyptians. Variations in the immune response could explain resistance to hepatitis C virus (HCV) infection. Toll‐like receptor gene (TLR)‐3 is an innate detector of dsRNA viruses, and the TLR‐9 gene recognizes bacterial and viral unmethylated cytosine–phosphate–guanosine (CpG) motifs. We previously reported that the TLR‐3.rs3775290 CC genotype was associated with HCV chronicity and that the TLR‐9 gene played no major role in this infection. This study identified the role of TLR‐3.rs3775290 (c.1377C/T), TLR‐9.rs5743836 (−1237T→C) and TLR‐9.rs352140 (G2848A) gene polymorphisms in predicting the outcome of HCV‐specific cell‐mediated immunity (CMI) among Egyptian health‐care workers (HCWs). We enrolled 265 HCWs in this study and divided them into four groups. Group 1: 140 seronegative‐aviraemic HCWs; group 2: 20 seronegative‐viraemic HCWs; group 3: 35 subjects with spontaneously resolved HCV infection; and group 4: 70 chronic HCV HCWs (patients). All subjects were genotyped by polymerase chain reaction–restriction fragment length polymorphism (PCR‐RFLP) analysis for the TLR‐3.rs3775290, TLR‐9.rs5743836 and TLR‐9.rs352140 single nucleotide polymorphisms (SNPs). We also quantified HCV‐specific CMI in the four groups using an interferon (IFN)‐γ enzyme‐linked immunospot (ELISPOT) assay in response to nine HCV genotype 4a, overlapping 15mer peptide pools covering the whole viral genome. No statistically significant difference was found between CMI‐responding subjects with different HCV states and TLR‐3.rs3775290 or TLR‐9.rs352140 genotypes. However, there was a significant relationship between the outcome of the HCV‐specific CMI and the TLR‐9.rs5743836 genotype among the responding subjects ( P = 0·005) and the chronic HCV patients ( P = 0·044). In conclusion, TLR‐9.rs5743836 SNP, but not TLR‐3.rs3775290 or TLR‐9.rs352140 genotypes, could predict the outcome of HCV‐specific CMI responses among Egyptians infected with genotype‐4. |
| Author | Rewisha, E. Hamdy, S. Osman, A. M. Waked, I. Sobhy, M. Abdelwahab, S. F. Hashem, M. Allam, W. R. Galal, I. Zakaria, Z. A. Abdel‐Samiee, M. |
| AuthorAffiliation | 7 Centre for Genomics University of Science and Technology Zewail City of Science and Technology Giza Egypt 3 Department of Microbiology and Immunology Faculty of Medicine Minia University Minia Egypt 1 The Egyptian Holding Company for Biological Products and Vaccines (VACSERA) Giza Egypt 2 Division of Microbiology Department of Pharmaceutics and Industrial Pharmacy Taif College of Pharmacy Al‐Haweiah, Taif Saudi Arabia 5 Biomedical Research Laboratory Faculty of Pharmacy Heliopolis University for Sustainable Development Cairo Egypt 6 Department of Epidemiology and Public Health University of Maryland School of Medicine Baltimore MD USA 8 Department of Hepatology and Gastroenterology National Liver Institute Menoufia University Menoufia Egypt 4 Department of Zoology Faculty of Science Cairo University Giza Egypt |
| AuthorAffiliation_xml | – name: 4 Department of Zoology Faculty of Science Cairo University Giza Egypt – name: 5 Biomedical Research Laboratory Faculty of Pharmacy Heliopolis University for Sustainable Development Cairo Egypt – name: 6 Department of Epidemiology and Public Health University of Maryland School of Medicine Baltimore MD USA – name: 7 Centre for Genomics University of Science and Technology Zewail City of Science and Technology Giza Egypt – name: 8 Department of Hepatology and Gastroenterology National Liver Institute Menoufia University Menoufia Egypt – name: 1 The Egyptian Holding Company for Biological Products and Vaccines (VACSERA) Giza Egypt – name: 3 Department of Microbiology and Immunology Faculty of Medicine Minia University Minia Egypt – name: 2 Division of Microbiology Department of Pharmaceutics and Industrial Pharmacy Taif College of Pharmacy Al‐Haweiah, Taif Saudi Arabia |
| Author_xml | – sequence: 1 givenname: S. F. orcidid: 0000-0002-9636-7485 surname: Abdelwahab fullname: Abdelwahab, S. F. email: icpminia@yahoo.com organization: Minia University – sequence: 2 givenname: S. surname: Hamdy fullname: Hamdy, S. organization: Cairo University – sequence: 3 givenname: A. M. surname: Osman fullname: Osman, A. M. organization: Cairo University – sequence: 4 givenname: Z. A. surname: Zakaria fullname: Zakaria, Z. A. organization: Heliopolis University for Sustainable Development – sequence: 5 givenname: I. surname: Galal fullname: Galal, I. organization: The Egyptian Holding Company for Biological Products and Vaccines (VACSERA) – sequence: 6 givenname: M. surname: Sobhy fullname: Sobhy, M. organization: The Egyptian Holding Company for Biological Products and Vaccines (VACSERA) – sequence: 7 givenname: M. surname: Hashem fullname: Hashem, M. organization: University of Maryland School of Medicine – sequence: 8 givenname: W. R. surname: Allam fullname: Allam, W. R. organization: Zewail City of Science and Technology – sequence: 9 givenname: M. surname: Abdel‐Samiee fullname: Abdel‐Samiee, M. organization: Menoufia University – sequence: 10 givenname: E. surname: Rewisha fullname: Rewisha, E. organization: Menoufia University – sequence: 11 givenname: I. surname: Waked fullname: Waked, I. organization: Menoufia University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32939755$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks9uGyEQxldVqsZJe-gLVEi9JAcnLMv-4VIpstw0kqVKlXteYXbwkuzCFthYvuUR-kh9lj5JJnYStZFaLjDwm49vYI6SA-ssJMn7lJ6lOM4VmLM0y1P-KpmkWZFPGePiIJlQSsVUpJQfJkchXGNYFAV7kxxmTGSizPNJ8usiBKeMjMZZ4jSJLZDBddve-aE1oX_aW7qu-333szM3QDwoGKLz5GS5-HaKuxmRtiEY4FqQNVgIZGNiS1oYUDmaQGbk1vgxIBAGUEYbRRTsJHto8HpoiOn70Zq4JW6MyvWoIXtn12S-3g7RSItqsostpijpgWycvwEf3iavtewCvHucj5Pvn-fL2Zfp4uvl1exiMVWcZ3yaVoLBSuRcMU21ZqIqG5nphucgS7kSKy0LVcmGVlQyXvFGlnlKqYaqSbVgRXacfNrrDuMKLSuw0cuuHrzppd_WTpr67xNr2nrtbuuy5DynDAVOHgW8-zFCiHVvwsMbSAtuDDVDn1XF86xC9OML9NqN3mJ5SJWUYxmCI_XhT0fPVp4-F4HTPaC8C8GDfkZSWj80To2NU-8aB9nzF6wycdcVWIzp_pexMR1s_y1dz-ZX-4x7fuDd2Q |
| CitedBy_id | crossref_primary_10_1016_j_mtbio_2022_100416 crossref_primary_10_17776_csj_1167703 crossref_primary_10_3389_fmicb_2023_1330170 crossref_primary_10_3389_fonc_2022_913231 crossref_primary_10_1093_cei_uxab031 crossref_primary_10_1097_MD_0000000000029758 crossref_primary_10_3390_ijms23105475 crossref_primary_10_1016_j_hbpd_2021_07_011 crossref_primary_10_1097_MRM_0000000000000355 crossref_primary_10_3389_fmicb_2023_1254805 |
| Cites_doi | 10.1074/jbc.M700209200 10.1002/hep.20666 10.1186/1471-2350-12-26 10.1128/CVI.00050-12 10.1007/s00705-018-3893-8 10.1056/NEJMcp1006613 10.1016/j.jhep.2008.01.028 10.1007/s11033-010-0607-z 10.1177/0300060513483398 10.1177/09680519040100040901 10.1177/0961203316659151 10.1002/hep.21996 10.1002/hep.23256 10.1128/JVI.00649-07 10.1016/j.jaut.2005.03.002 10.1084/jem.20050338 10.1074/jbc.M414139200 10.1053/jhep.2001.20794 10.1016/j.virol.2004.01.033 10.1111/j.1398-9995.2007.01358.x 10.1155/2018/9127146 10.1002/hep.22759 10.1128/JVI.77.11.6367-6375.2003 10.1111/j.1365-3024.2005.00762.x 10.1128/IAI.01226-09 10.4049/jimmunol.178.7.4436 10.1073/pnas.0408824102 10.1126/science.1082604 10.1186/s13027-016-0070-0 10.3748/wjg.v12.i8.1198 10.3349/ymj.2014.55.2.428 10.1097/MD.0000000000002302 |
| ContentType | Journal Article |
| Copyright | 2020 British Society for Immunology 2020 British Society for Immunology. 2021 British Society for Immunology |
| Copyright_xml | – notice: 2020 British Society for Immunology – notice: 2020 British Society for Immunology. – notice: 2021 British Society for Immunology |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 M7N 7X8 5PM |
| DOI | 10.1111/cei.13514 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| DocumentTitleAlternate | TLR‐3 and ‐9 SNPs in HCV‐infected Egyptians |
| EISSN | 1365-2249 |
| EndPage | 12 |
| ExternalDocumentID | PMC7744502 32939755 10_1111_cei_13514 CEI13514 |
| Genre | article Clinical Trial Research Support, Non-U.S. Gov't Journal Article Commentary Editorial |
| GrantInformation_xml | – fundername: The Egyptian Science and Technology Development Fund (STDF) funderid: 1664 – fundername: The Egyptian Science and Technology Development Fund (STDF) grantid: 1664 |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 169 1OC 24P 29B 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 5WD 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 A8Z AABZA AACZT AAESR AAEVG AAHHS AAONW AAPXW AARHZ AAUAY AAVAP AAZKR ABCQN ABCUV ABDBF ABDFA ABEJV ABEML ABJNI ABLJU ABNHQ ABOCM ABPTD ABPVW ABQNK ABXVV ACAHQ ACCFJ ACFBH ACGFO ACGFS ACMXC ACPOU ACPRK ACSCC ACUFI ACUHS ACXQS ADBBV ADEOM ADIPN ADIYS ADIZJ ADKYN ADMGS ADOZA ADQBN ADVEK ADXAS ADZMN ADZOD AEEZP AEGXH AEIMD AENEX AEQDE AEUQT AFBPY AFEBI AFFZL AFGKR AFPWT AFRAH AFTUV AFXAL AFZJQ AGMDO AGUTN AHMMS AIACR AIAGR AIURR AIWBW AJAOE AJBDE AJEEA ALAGY ALMA_UNASSIGNED_HOLDINGS AMBMR AMYDB AOIJS ATGXG ATUGU AZBYB AZVAB BAFTC BAWUL BCRHZ BEYMZ BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EAS EBB EBC EBD EBS EBX EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FIJ FUBAC G-S G.N GODZA GX1 H.X H13 HF~ HZI HZ~ IH2 IHE IPNFZ IX1 J0M J5H K48 KBUDW KBYEO KOP KSI KSN LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NOMLY NU- O66 O9- OAUYM OBS OCZFY OHT OIG OJZSN OK1 OPAEJ OVD OWPYF P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 Q~Q R.K ROL ROX RPM RX1 SUPJJ SV3 TEORI TR2 TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOQ WOW WQJ WRC WVDHM WXI X7M XG1 Y6R YFH YOC YUY ZGI ZXP ZZTAW ~IA ~KM ~WT AAFWJ AAYXX ABGNP ABVGC AEMQT AGORE AJBYB AJNCP ALXQX CITATION AAMMB ACVCV AEFGJ AFFQV AGXDD AHGBF AIDQK AIDYY AJDVS CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 M7N 7X8 5PM |
| ID | FETCH-LOGICAL-c4434-1892eb954c2f0ff2987da3fd45ea7ab9bfa6c8ad080a2484da75100fe8d1f9263 |
| IEDL.DBID | DR2 |
| ISSN | 0009-9104 1365-2249 |
| IngestDate | Thu Aug 21 18:26:35 EDT 2025 Fri Jul 11 04:27:20 EDT 2025 Wed Aug 13 03:20:31 EDT 2025 Mon Jul 21 06:00:46 EDT 2025 Tue Jul 01 03:53:11 EDT 2025 Thu Apr 24 22:56:49 EDT 2025 Wed Jan 22 16:32:58 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | health-care workers TLR-3 SNP TLR-9 HCV CMI cell-mediated immunity |
| Language | English |
| License | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model 2020 British Society for Immunology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4434-1892eb954c2f0ff2987da3fd45ea7ab9bfa6c8ad080a2484da75100fe8d1f9263 |
| Notes | These authors contributed equally to this work. SourceType-Scholarly Journals-1 content type line 14 ObjectType-Editorial-2 ObjectType-Commentary-1 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| ORCID | 0000-0002-9636-7485 |
| OpenAccessLink | https://academic.oup.com/cei/article-pdf/203/1/3/41635265/cei13514.pdf |
| PMID | 32939755 |
| PQID | 2470495494 |
| PQPubID | 36527 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7744502 proquest_miscellaneous_2443884538 proquest_journals_2470495494 pubmed_primary_32939755 crossref_primary_10_1111_cei_13514 crossref_citationtrail_10_1111_cei_13514 wiley_primary_10_1111_cei_13514_CEI13514 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January 2021 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: January 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford – name: Hoboken |
| PublicationTitle | Clinical and experimental immunology |
| PublicationTitleAlternate | Clin Exp Immunol |
| PublicationYear | 2021 |
| Publisher | Oxford University Press John Wiley and Sons Inc |
| Publisher_xml | – name: Oxford University Press – name: John Wiley and Sons Inc |
| References | 2010; 78 2018; 163 2004; 322 2006; 12 2007; 282 2017; 26 2013; 41 2005; 41 2012; 19 2016; 95 2011; 12 2011; 38 2005; 27 2007; 34 2009; 49 2011; 134 2003; 77 2005; 24 2016; 11 2004; 10 2005; 280 2007; 178 2018; 2018 1999; 19 2005; 102 2005; 202 2000; 11 2008; 47 2008; 48 2007; 81 2016 2007; 62 2001; 33 2003; 300 2018; 31 2011; 364 2010; 51 2014; 55 Li (2023081113342779200_cei13514-bib-0004) 2005; 280 Davidson (2023081113342779200_cei13514-bib-0015) 1999; 19 Novak (2023081113342779200_cei13514-bib-0026) 2007; 62 Lange (2023081113342779200_cei13514-bib-0034) 2011; 12 Chuang (2023081113342779200_cei13514-bib-0036) 2000; 11 Pandey (2023081113342779200_cei13514-bib-0016) 2011; 38 Fischer (2023081113342779200_cei13514-bib-0032) 2016 Abdelwahab (2023081113342779200_cei13514-bib-0018) 2012; 19 Christensen (2023081113342779200_cei13514-bib-0027) 2005; 202 Ghany (2023081113342779200_cei13514-bib-0002) 2009; 49 Yonkers (2023081113342779200_cei13514-bib-0013) 2007; 178 Farid (2023081113342779200_cei13514-bib-0019) 2005; 27 Aslam (2023081113342779200_cei13514-bib-0033) 2018; 31 Broering (2023081113342779200_cei13514-bib-0005) 2008; 48 Dolganiuc (2023081113342779200_cei13514-bib-0006) 2006; 12 Kikuchi (2023081113342779200_cei13514-bib-0035) 2005; 24 Otsuka (2023081113342779200_cei13514-bib-0010) 2005; 41 Ng (2023081113342779200_cei13514-bib-0031) 2010; 78 Foy (2023081113342779200_cei13514-bib-0009) 2003; 300 Geiss (2023081113342779200_cei13514-bib-0007) 2003; 77 Fukuda (2023081113342779200_cei13514-bib-0012) 2001; 33 Ranjith-Kumar (2023081113342779200_cei13514-bib-0024) 2007; 282 Chang (2023081113342779200_cei13514-bib-0023) 2010; 51 Rosen (2023081113342779200_cei13514-bib-0003) 2011; 364 Abe (2023081113342779200_cei13514-bib-0011) 2007; 81 Li (2023081113342779200_cei13514-bib-0022) 2005; 102 Tian (2023081113342779200_cei13514-bib-0038) 2018; 2018 Abdelwahab (2023081113342779200_cei13514-bib-0001) 2016; 11 Hamdy (2023081113342779200_cei13514-bib-0014) 2018; 163 Medhi (2023081113342779200_cei13514-bib-0029) 2011; 134 Demirci (2023081113342779200_cei13514-bib-0017) 2007; 34 Edelmann (2023081113342779200_cei13514-bib-0020) 2004; 322 Geng (2023081113342779200_cei13514-bib-0025) 2016; 95 Yusuf (2023081113342779200_cei13514-bib-0028) 2017; 26 Wei (2023081113342779200_cei13514-bib-0030) 2014; 55 Shiina (2023081113342779200_cei13514-bib-0008) 2008; 47 Takeuchi (2023081113342779200_cei13514-bib-0021) 2004; 10 Lai (2023081113342779200_cei13514-bib-0037) 2013; 41 |
| References_xml | – volume: 163 start-page: 2433 year: 2018 end-page: 42 article-title: Association of Toll‐like receptor 3 and Toll‐like receptor 9 single‐nucleotide polymorphisms with hepatitis C virus persistence among Egyptians publication-title: Arch Virol – volume: 24 start-page: 347 year: 2005 end-page: 52 article-title: Genetic polymorphisms of toll‐like receptor 9 influence the immune response to CpG and contribute to hyper‐IgM in primary biliary cirrhosis publication-title: J Autoimmun – volume: 78 start-page: 1345 year: 2010 end-page: 52 article-title: Increase in NF‐kappaB binding affinity of the variant C allele of the toll‐like receptor 9–1237T/C polymorphism is associated with ‐induced gastric disease publication-title: Infect Immun – volume: 31 start-page: 2709 year: 2018 end-page: 14 article-title: Analysis of toll‐like receptors‐9 (TLR9) gene polymorphism (rs5743836) in Pakistani patients with HCV publication-title: Pak J Pharm Sci – volume: 95 year: 2016 article-title: Toll‐Like receptor 3 is associated with the risk of HCV Infection and HBV‐related diseases publication-title: Medicine – volume: 49 start-page: 1335 year: 2009 end-page: 74 article-title: American Association for the Study of Liver Disease. Diagnosis, management, and treatment of hepatitis C: an update publication-title: Hepatology – volume: 48 start-page: 914 year: 2008 end-page: 22 article-title: Toll‐like receptor‐stimulated non‐parenchymal liver cells can regulate hepatitis C virus replication publication-title: J Hepatol – volume: 62 start-page: 766 year: 2007 end-page: 72 article-title: Putative association of a TLR9 promoter polymorphism with atopic eczema publication-title: Allergy – volume: 81 start-page: 8953 year: 2007 end-page: 66 article-title: Hepatitis C virus nonstructural protein 5A modulates the toll‐like receptor‐MyD88‐dependent signaling pathway in macrophage cell lines publication-title: J Virol – volume: 322 start-page: 231 year: 2004 end-page: 8 article-title: Does Toll‐like receptor 3 play a biological role in virus infections? publication-title: Virology – volume: 38 start-page: 4715 year: 2011 end-page: 21 article-title: Evaluation of Toll‐like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms in cervical cancer susceptibility publication-title: Mol Biol Rep – volume: 41 start-page: 1027 year: 2013 end-page: 36 article-title: Toll‐like receptor 9 (TLR9) gene polymorphisms associated with increased susceptibility of human papillomavirus‐16 infection in patients with cervical cancer publication-title: J Int Med Res – volume: 19 start-page: 175 year: 1999 end-page: 81 article-title: Determination of HCV genotypes by RFLP publication-title: Methods Mol Med – volume: 27 start-page: 189 year: 2005 end-page: 96 article-title: Schistosoma infection inhibits cellular immune responses to core HCV peptides publication-title: Parasite Immunol – volume: 55 start-page: 428 year: 2014 end-page: 34 article-title: Single nucleotide polymorphisms of toll‐like receptor 7 and toll‐like receptor 9 in hepatitis C virus infection patients from central China publication-title: Yonsei Med J – volume: 47 start-page: 385 year: 2008 end-page: 95 article-title: Cell culture‐produced hepatitis C virus impairs plasmacytoid dendritic cell function publication-title: Hepatology – volume: 12 start-page: 1198 year: 2006 end-page: 204 article-title: Distinct Toll‐like receptor expression in monocytes and T cells in chronic HCV infection publication-title: World J Gastroenterol – volume: 19 start-page: 780 year: 2012 end-page: 6 article-title: Hepatitis C virus‐multispecific T‐cell responses without viremia or seroconversion among Egyptian health care workers at high risk of infection publication-title: Clin Vaccine Immunol – volume: 202 start-page: 321 year: 2005 end-page: 31 article-title: Toll‐like receptor 9 controls anti‐DNA autoantibody production in murine lupus publication-title: J Exp Med – volume: 77 start-page: 6367 year: 2003 end-page: 75 article-title: Gene expression profiling of the cellular transcriptional network regulated by alpha/beta interferon and its partial attenuation by the hepatitis C virus nonstructural 5A protein publication-title: J Virol – volume: 300 start-page: 1145 year: 2003 end-page: 8 article-title: Regulation of interferon regulatory factor‐3 by the hepatitis C virus serine protease publication-title: Science – volume: 51 start-page: 35 year: 2010 end-page: 42 article-title: Impaired expression and function of toll‐like receptor 7 in hepatitis C virus infection in human hepatoma cells publication-title: Hepatology – volume: 2018 start-page: 9127146 year: 2018 article-title: The associations between Toll‐like receptor 9 gene polymorphisms and cervical cancer susceptibility publication-title: Mediat Inflamm – volume: 26 start-page: 307 year: 2017 end-page: 10 article-title: Genetic selection pressure in TLR9 gene may enforce risk for SLE in Indian Tamils publication-title: Lupus – volume: 134 start-page: 200 year: 2011 end-page: 7 article-title: Promoter region polymorphism & expression profile of toll like receptor‐3 (TLR‐3) gene in chronic hepatitis C virus (HCV) patients from India publication-title: Ind J Med Res – volume: 10 start-page: 252 year: 2004 end-page: 6 article-title: Interferon response induced by Toll‐like receptor signaling publication-title: J Endotoxin Res – year: 2016 article-title: Sex‐specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection publication-title: Gut – volume: 11 start-page: 23 year: 2016 article-title: Cellular immune response to hepatitis‐C‐virus in subjects without viremia or seroconversion: is it important? publication-title: Infect Agents Cancer – volume: 41 start-page: 1004 year: 2005 end-page: 12 article-title: Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses publication-title: Hepatology – volume: 33 start-page: 159 year: 2001 end-page: 65 article-title: Hepatitis C virus core protein enhances the activation of the transcription factor, Elk1, in response to mitogenic stimuli publication-title: Hepatology – volume: 178 start-page: 4436 year: 2007 end-page: 44 article-title: TLR ligand‐dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection publication-title: J Immunol – volume: 364 start-page: 2429 year: 2011 end-page: 38 article-title: Clinical practice. Chronic hepatitis C infection publication-title: N Engl J Med – volume: 34 start-page: 1708 year: 2007 end-page: 11 article-title: Association study of Toll‐like receptor 5 (TLR5) and Toll‐like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosus publication-title: J Rheumatol – volume: 12 start-page: 26 year: 2011 article-title: Comprehensive genetic assessment of a functional TLR9 promoter polymorphism: no replicable association with asthma or asthma‐related phenotypes publication-title: BMC Med Genet – volume: 102 start-page: 2992 year: 2005 end-page: 7 article-title: Immune evasion by hepatitis C virus NS3/4A protease‐mediated cleavage of the Toll‐like receptor 3 adaptor protein TRIF publication-title: Proc Natl Acad Sci USA – volume: 11 start-page: 372 year: 2000 end-page: 8 article-title: Cloning and characterization of a sub‐family of human toll‐like receptors: hTLR7, hTLR8 and hTLR9 publication-title: Eur Cytokine Netw – volume: 280 start-page: 16739 year: 2005 end-page: 47 article-title: Distinct poly(I‐C) and virus‐activated signaling pathways leading to interferon‐beta production in hepatocytes publication-title: J Biol Chem – volume: 282 start-page: 17696 year: 2007 end-page: 705 article-title: Effects of single nucleotide polymorphisms on Toll‐like receptor 3 activity and expression in cultured cells publication-title: J Biol Chem – volume: 282 start-page: 17696 year: 2007 ident: 2023081113342779200_cei13514-bib-0024 article-title: Effects of single nucleotide polymorphisms on Toll-like receptor 3 activity and expression in cultured cells publication-title: J Biol Chem doi: 10.1074/jbc.M700209200 – volume: 41 start-page: 1004 year: 2005 ident: 2023081113342779200_cei13514-bib-0010 article-title: Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses publication-title: Hepatology doi: 10.1002/hep.20666 – volume: 12 start-page: 26 year: 2011 ident: 2023081113342779200_cei13514-bib-0034 article-title: Comprehensive genetic assessment of a functional TLR9 promoter polymorphism: no replicable association with asthma or asthma-related phenotypes publication-title: BMC Med Genet doi: 10.1186/1471-2350-12-26 – volume: 19 start-page: 780 year: 2012 ident: 2023081113342779200_cei13514-bib-0018 article-title: Hepatitis C virus-multispecific T-cell responses without viremia or seroconversion among Egyptian health care workers at high risk of infection publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00050-12 – volume: 163 start-page: 2433 year: 2018 ident: 2023081113342779200_cei13514-bib-0014 article-title: Association of Toll-like receptor 3 and Toll-like receptor 9 single-nucleotide polymorphisms with hepatitis C virus persistence among Egyptians publication-title: Arch Virol doi: 10.1007/s00705-018-3893-8 – volume: 364 start-page: 2429 year: 2011 ident: 2023081113342779200_cei13514-bib-0003 article-title: Clinical practice. Chronic hepatitis C infection publication-title: N Engl J Med doi: 10.1056/NEJMcp1006613 – volume: 48 start-page: 914 year: 2008 ident: 2023081113342779200_cei13514-bib-0005 article-title: Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication publication-title: J Hepatol doi: 10.1016/j.jhep.2008.01.028 – volume: 38 start-page: 4715 year: 2011 ident: 2023081113342779200_cei13514-bib-0016 article-title: Evaluation of Toll-like receptors 3 (c.1377C/T) and 9 (G2848A) gene polymorphisms in cervical cancer susceptibility publication-title: Mol Biol Rep doi: 10.1007/s11033-010-0607-z – volume: 41 start-page: 1027 year: 2013 ident: 2023081113342779200_cei13514-bib-0037 article-title: Toll-like receptor 9 (TLR9) gene polymorphisms associated with increased susceptibility of human papillomavirus-16 infection in patients with cervical cancer publication-title: J Int Med Res doi: 10.1177/0300060513483398 – volume: 10 start-page: 252 year: 2004 ident: 2023081113342779200_cei13514-bib-0021 article-title: Interferon response induced by Toll-like receptor signaling publication-title: J Endotoxin Res doi: 10.1177/09680519040100040901 – year: 2016 ident: 2023081113342779200_cei13514-bib-0032 article-title: Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection publication-title: Gut – volume: 134 start-page: 200 year: 2011 ident: 2023081113342779200_cei13514-bib-0029 article-title: Promoter region polymorphism & expression profile of toll like receptor-3 (TLR-3) gene in chronic hepatitis C virus (HCV) patients from India publication-title: Ind J Med Res – volume: 34 start-page: 1708 year: 2007 ident: 2023081113342779200_cei13514-bib-0017 article-title: Association study of Toll-like receptor 5 (TLR5) and Toll-like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosus publication-title: J Rheumatol – volume: 26 start-page: 307 year: 2017 ident: 2023081113342779200_cei13514-bib-0028 article-title: Genetic selection pressure in TLR9 gene may enforce risk for SLE in Indian Tamils publication-title: Lupus doi: 10.1177/0961203316659151 – volume: 47 start-page: 385 year: 2008 ident: 2023081113342779200_cei13514-bib-0008 article-title: Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function publication-title: Hepatology doi: 10.1002/hep.21996 – volume: 51 start-page: 35 year: 2010 ident: 2023081113342779200_cei13514-bib-0023 article-title: Impaired expression and function of toll-like receptor 7 in hepatitis C virus infection in human hepatoma cells publication-title: Hepatology doi: 10.1002/hep.23256 – volume: 81 start-page: 8953 year: 2007 ident: 2023081113342779200_cei13514-bib-0011 article-title: Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines publication-title: J Virol doi: 10.1128/JVI.00649-07 – volume: 24 start-page: 347 year: 2005 ident: 2023081113342779200_cei13514-bib-0035 article-title: Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis publication-title: J Autoimmun doi: 10.1016/j.jaut.2005.03.002 – volume: 202 start-page: 321 year: 2005 ident: 2023081113342779200_cei13514-bib-0027 article-title: Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus publication-title: J Exp Med doi: 10.1084/jem.20050338 – volume: 31 start-page: 2709 year: 2018 ident: 2023081113342779200_cei13514-bib-0033 article-title: Analysis of toll-like receptors-9 (TLR9) gene polymorphism (rs5743836) in Pakistani patients with HCV publication-title: Pak J Pharm Sci – volume: 280 start-page: 16739 year: 2005 ident: 2023081113342779200_cei13514-bib-0004 article-title: Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes publication-title: J Biol Chem doi: 10.1074/jbc.M414139200 – volume: 33 start-page: 159 year: 2001 ident: 2023081113342779200_cei13514-bib-0012 article-title: Hepatitis C virus core protein enhances the activation of the transcription factor, Elk1, in response to mitogenic stimuli publication-title: Hepatology doi: 10.1053/jhep.2001.20794 – volume: 322 start-page: 231 year: 2004 ident: 2023081113342779200_cei13514-bib-0020 article-title: Does Toll-like receptor 3 play a biological role in virus infections? publication-title: Virology doi: 10.1016/j.virol.2004.01.033 – volume: 62 start-page: 766 year: 2007 ident: 2023081113342779200_cei13514-bib-0026 article-title: Putative association of a TLR9 promoter polymorphism with atopic eczema publication-title: Allergy doi: 10.1111/j.1398-9995.2007.01358.x – volume: 2018 start-page: 9127146 year: 2018 ident: 2023081113342779200_cei13514-bib-0038 article-title: The associations between Toll-like receptor 9 gene polymorphisms and cervical cancer susceptibility publication-title: Mediat Inflamm doi: 10.1155/2018/9127146 – volume: 11 start-page: 372 year: 2000 ident: 2023081113342779200_cei13514-bib-0036 article-title: Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9 publication-title: Eur Cytokine Netw – volume: 49 start-page: 1335 year: 2009 ident: 2023081113342779200_cei13514-bib-0002 article-title: American Association for the Study of Liver Disease. Diagnosis, management, and treatment of hepatitis C: an update publication-title: Hepatology doi: 10.1002/hep.22759 – volume: 19 start-page: 175 year: 1999 ident: 2023081113342779200_cei13514-bib-0015 article-title: Determination of HCV genotypes by RFLP publication-title: Methods Mol Med – volume: 77 start-page: 6367 year: 2003 ident: 2023081113342779200_cei13514-bib-0007 article-title: Gene expression profiling of the cellular transcriptional network regulated by alpha/beta interferon and its partial attenuation by the hepatitis C virus nonstructural 5A protein publication-title: J Virol doi: 10.1128/JVI.77.11.6367-6375.2003 – volume: 27 start-page: 189 year: 2005 ident: 2023081113342779200_cei13514-bib-0019 article-title: Schistosoma infection inhibits cellular immune responses to core HCV peptides publication-title: Parasite Immunol doi: 10.1111/j.1365-3024.2005.00762.x – volume: 78 start-page: 1345 year: 2010 ident: 2023081113342779200_cei13514-bib-0031 article-title: Increase in NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9–1237T/C polymorphism is associated with Helicobacter pylori-induced gastric disease publication-title: Infect Immun doi: 10.1128/IAI.01226-09 – volume: 178 start-page: 4436 year: 2007 ident: 2023081113342779200_cei13514-bib-0013 article-title: TLR ligand-dependent activation of naive CD4 T cells by plasmacytoid dendritic cells is impaired in hepatitis C virus infection publication-title: J Immunol doi: 10.4049/jimmunol.178.7.4436 – volume: 102 start-page: 2992 year: 2005 ident: 2023081113342779200_cei13514-bib-0022 article-title: Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0408824102 – volume: 300 start-page: 1145 year: 2003 ident: 2023081113342779200_cei13514-bib-0009 article-title: Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease publication-title: Science doi: 10.1126/science.1082604 – volume: 11 start-page: 23 year: 2016 ident: 2023081113342779200_cei13514-bib-0001 article-title: Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important? publication-title: Infect Agents Cancer doi: 10.1186/s13027-016-0070-0 – volume: 12 start-page: 1198 year: 2006 ident: 2023081113342779200_cei13514-bib-0006 article-title: Distinct Toll-like receptor expression in monocytes and T cells in chronic HCV infection publication-title: World J Gastroenterol doi: 10.3748/wjg.v12.i8.1198 – volume: 55 start-page: 428 year: 2014 ident: 2023081113342779200_cei13514-bib-0030 article-title: Single nucleotide polymorphisms of toll-like receptor 7 and toll-like receptor 9 in hepatitis C virus infection patients from central China publication-title: Yonsei Med J doi: 10.3349/ymj.2014.55.2.428 – volume: 95 year: 2016 ident: 2023081113342779200_cei13514-bib-0025 article-title: Toll-Like receptor 3 is associated with the risk of HCV Infection and HBV-related diseases publication-title: Medicine doi: 10.1097/MD.0000000000002302 |
| SSID | ssj0006662 |
| Score | 2.3730764 |
| Snippet | We previously reported that TLR3.rs3775290 ‘CC’ genotype was associated with HCV chronicity, while TLR9 gene played no role in this infection. Herein, we show... Variations in the immune response could explain resistance to hepatitis C virus (HCV) infection. Toll-like receptor gene (TLR)-3 is an innate detector of dsRNA... Variations in the immune response could explain resistance to hepatitis C virus (HCV) infection. Toll‐like receptor gene (TLR)‐3 is an innate detector of dsRNA... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 3 |
| SubjectTerms | Adult cell‐mediated immunity Chronic infection CMI CpG islands Cytosine Disease resistance Double-stranded RNA Editors' Choice Enzyme-linked immunosorbent assay Female Gene polymorphism Genomes Genotype & phenotype HCV Health care Health Personnel health‐care workers Hepacivirus - genetics Hepacivirus - immunology Hepatitis Hepatitis C Hepatitis C, Chronic - genetics Hepatitis C, Chronic - immunology Humans Immune response Immunity, Cellular Infections Interferon Male Middle Aged Original Polymerase chain reaction Polymorphism Polymorphism, Single Nucleotide Restriction fragment length polymorphism Single-nucleotide polymorphism SNP Statistical analysis TLR‐3 TLR‐9 Toll-Like Receptor 3 - genetics Toll-Like Receptor 3 - immunology Toll-Like Receptor 9 - genetics Toll-Like Receptor 9 - immunology Toll-like receptors |
| Title | Association of the polymorphism of the Toll‐like receptor (TLR)‐3 and TLR‐9 genes with hepatitis C virus‐specific cell‐mediated immunity outcomes among Egyptian health‐care workers |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcei.13514 https://www.ncbi.nlm.nih.gov/pubmed/32939755 https://www.proquest.com/docview/2470495494 https://www.proquest.com/docview/2443884538 https://pubmed.ncbi.nlm.nih.gov/PMC7744502 |
| Volume | 203 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLaqSiAuLGUbWpBBHMohVcZxFosTGk0piHKoptIckCLbsWnUaTJqkkrDiZ_AT-K38Et4z1mYoSAhLlESvyyO3_LZeQshL7VSVo_jyDNgzD2ehL4nhNKeZGGiwOJoxTEa-fhjdHTK38_D-RZ53cfCtPkhhgU3lAynr1HAparWhFybHIs2uCLW6KuFgOjkV-oogOWsr6IGJpF3WYXQi2e4ctMWXQOY1_0k1_GrM0CHd8in_tVbv5Pzg6ZWB_rLb1kd_7Nvd8ntDpjSNy0n3SNbptghN9pSlasdcvO4-wl_n3xfG1JaWgoQki7LxeqihDHLq4v-3AxY7MfXb4v83FDQq2YJ03u6P_tw8grOBlQWGYUD2Bf0M2pcimvC9Mygj3edV3RCr_LLpgICDAdFlyaKvxng2IW7AFSmuYtuqVe0bGroI9zDFU-iUyyuBoxP2zBPuAQ93Cg6oQHcfUBOD6ezyZHXFYLwNOcB98aJYEaJkGtmfWuZSOJMBjbjoZGxVEJZGelEZoB-JeMJz2QMqsa3JsnGVrAoeEi2i7Iwjwk1hmkN9jiwcONMaJGxIJIRV9w3sa_kiOz3LJHqLks6FutYpP1sCcYmdWMzIi8G0mWbGuRPRHs9X6WddqhSxmOYmMHMHJqfD80g1_gVZWHKBml4kCQc7NGIPGrZcHhKABhNxGE4IvEGgw4EmDN8s6XIz1zucED7PPQZdNPx399fPJ1M37mdJ_9OuktuMXT5cStUe2S7vmzMU8BstXrmhBO2b-fjn2yHR_o |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9NAFB5VRSwXlrIFCgyIQzm4csbjZSQuKEqVQtJDlUq9IGtmPEOtpnbUOEjhxE_gJ_Fb-CW8N15IKEiIm-15djyZt3xv_BZCXmulrO7HkWfAmHs8CX1PCKU9ycJEgcXRimM28uQoGp3w96fh6RZ52-bC1PUhug03lAynr1HAcUN6Tcq1ybFrA3axvoYdvZ1DdfyreBQAc9b2UQOjyJu6QhjH0926aY2uQMyrkZLrCNaZoIM75GP78nXkyfn-slL7-stvdR3_d3Z3ye0Gm9J3NTPdI1um2CHX626Vqx1yY9J8h79Pvq-tKi0tBRRJ5-VsdVHCsuWLi_baFLjsx9dvs_zcUFCtZg4ePt2bjo_fwNWAyiKjcALHgn5CpUtxW5ieGQzzrvIFHdDP-eVyAQSYEYpRTRS_NMC5y3gBtExzl-BSrWi5rGCS8AzXP4kOsb8a8D6tMz3hFgxyoxiHBoj3ATk5GE4HI6_pBeFpzgPu9RPBjBIh18z61jKRxJkMbMZDI2OphLIy0onMAABLxhOeyRi0jW9NkvWtYFHwkGwXZWEeE2oM0xpMcmDhwZnQImNBJCOuuG9iX8ke2Wt5ItVNoXTs1zFLW4cJ1iZ1a9MjrzrSeV0d5E9Euy1jpY2CWKSMx-CbgXMOwy-7YRBt_BdlYcol0vAgSTiYpB55VPNh9ysBwDQRh2GPxBsc2hFg2fDNkSI_c-XDAfDz0GcwTceAf3_xdDA8dAdP_p30Bbk5mk7G6fjw6MNTcothBJDbsNol29Xl0jwDCFep505SfwLgpEsk |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLamISZeuAwYhQEG8TAeMqWOc7F4Ql2rDbYJTZ20B6TIdmwWrUuqNUUqT_wEfhK_hV_COc6FloGEeEvik8SOz-Wzcy6EvNJKWd2PI8-AMfd4EvqeEEp7koWJAoujFcdo5KPjaP-UvzsLz9bImzYWps4P0W24oWQ4fY0CPs3skpBrk2PRBixifYNHfoIsvXfyK3cU4HLWllEDm8ibtELoxtPdumqMriHM646SywDWWaDRHfKx7XvteHKxO6_Urv7yW1rH_xzcXXK7Qab0bc1K98iaKTbJzbpW5WKTbBw1f-Hvk-9Lc0pLSwFD0mk5WVyWMGn57LK9NgYe-_H12yS_MBQUq5nC-p7ujA9PXsPVgMoio3ACx4J-QpVLcVOYnht08q7yGR3Qz_nVfAYEGA-KPk0U_zPAuYt3AaxMcxfeUi1oOa9gjPAMVz2JDrG6GnA-reM84RZ0caPohQZ49wE5HQ3Hg32vqQThac4D7vUTwYwSIdfM-tYykcSZDGzGQyNjqYSyMtKJzAD-SsYTnskYdI1vTZL1rWBR8JCsF2VhHhFqDNMaDHJg4cGZ0CJjQSQjrrhvYl_JHtlpWSLVTZp0rNYxSdvlEsxN6uamR152pNM6N8ifiLZbvkob9TBLGY9hZQZLc2h-0TWDYONXlIUp50jDgyThYJB6ZKtmw-4tAYA0EYdhj8QrDNoRYNLw1ZYiP3fJwwHu89BnMEzHf3_veDoYHriDx_9O-pxsfNgbpYcHx--fkFsM3X_cbtU2Wa-u5uYp4LdKPXNy-hMEA0nc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+of+the+polymorphism+of+the+Toll-like+receptor+%28TLR%29-3+and+TLR-9+genes+with+hepatitis+C+virus-specific+cell-mediated+immunity+outcomes+among+Egyptian+health-care+workers&rft.jtitle=Clinical+and+experimental+immunology&rft.au=Abdelwahab%2C+S+F&rft.au=Hamdy%2C+S&rft.au=Osman%2C+A+M&rft.au=Zakaria%2C+Z+A&rft.date=2021-01-01&rft.issn=0009-9104&rft.eissn=1365-2249&rft.volume=203&rft.issue=1&rft.spage=3&rft.epage=12&rft_id=info:doi/10.1111%2Fcei.13514&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_cei_13514 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-9104&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-9104&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-9104&client=summon |